Mass Tort Research

Talcum Powder Settlements: J&J’s $5.5 Billion 2026 Proposal

On July 27, 2026, Johnson & Johnson announced a $5.5 billion commitment to resolve the ovarian talc litigation — but only if at least 95% of remaining claims take part. Here is what the court record actually shows about amounts, case counts, and timing.

Figures on this page are sourced to J&J’s Form 8-K filed with the SEC on July 27, 2026 and the JPML pending-case report dated August 3, 2026. Last reviewed August 14, 2026.

Updated August 14, 2026 — earlier figures superseded

Until August 2026 this page described an $8.9 billion fund, ~100,000 pending claims and a 75% approval threshold. Those numbers came from Johnson & Johnson’s bankruptcy plans, both of which courts rejected. The live proposal is a civil settlement with different terms. The failed plans are still explained below, because the history is what makes the current deal understandable.

$5.5B

J&J Commitment (Proposed)

Announced July 27, 2026 — SEC Form 8-K

95%

Required Participation

Deal is void below this threshold

68,914

Pending MDL 2738 Cases

JPML report, August 3, 2026

2027

Earliest Payments

Up to $3B in 2027; nothing more before 2028

Sources: Johnson & Johnson, Form 8-K (Item 7.01), July 27, 2026 · JPML, Pending MDL Dockets by Actions Pending, August 3, 2026 (PDF). Nothing here is final: as of this update the proposal had not been accepted, and no claims administrator has been appointed.

Background: Why Talcum Powder Lawsuits Exist

Tens of thousands of lawsuits allege that Johnson & Johnson’s talc-based products, including Baby Powder and Shower to Shower, were contaminated with asbestos and caused ovarian cancer and mesothelioma. The litigation gained momentum after internal J&J documents surfaced in a 2018 Reuters investigation indicating the company had known about potential asbestos contamination for decades. J&J has consistently denied that its talc products cause cancer or contained asbestos, and continues to deny it in the 2026 proposal.

J&J discontinued talc-based Baby Powder in the United States and Canada in 2020 and globally in 2023, switching to a cornstarch-based formula.

The federal cases are consolidated in the U.S. District Court for the District of New Jersey before Judge Michael A. Shipp as In re: Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation, MDL No. 2738. As of the JPML report dated August 3, 2026, that docket held 68,914 pending actions out of 71,601 filed historically. Thousands of additional cases sit in state courts and are not counted in that figure.

Key Timeline

Three attempts to end this litigation through bankruptcy failed before J&J returned to civil court. That sequence explains why older “settlement amounts” still circulate online.

2018

A Reuters investigation reports that J&J knew about asbestos findings in its talc for decades. Filings surge nationwide.

2018

A St. Louis jury awards $4.69 billion to 22 women alleging talc caused ovarian cancer — later reduced to roughly $2.12 billion on appeal.

2020

J&J discontinues talc-based Baby Powder in the U.S. and Canada; the global discontinuation follows in 2023.

2021

J&J moves talc liabilities into a subsidiary, LTL Management, and puts it into Chapter 11 — the "Texas Two-Step." The Third Circuit orders the case dismissed in 2023.

Apr 2023

In a second Chapter 11, J&J proposes an $8.9 billion fund payable over 25 years. This is the origin of the "$8.9 billion settlement" figure still quoted across the web.

Jul 2023

Judge Michael Kaplan (Bankr. D.N.J.) dismisses that second bankruptcy for lack of immediate financial distress — "the court smells smoke, but does not see the fire." The $8.9 billion plan dies with it.

2024

J&J proposes a roughly $6.5 billion ovarian-only plan and, in September, places a new subsidiary, Red River Talc, into a prepackaged Chapter 11 requiring a 75% claimant vote.

Mar 2025

Judge Christopher Lopez (Bankr. S.D. Tex.) denies confirmation and dismisses the Red River case, citing voting and solicitation irregularities. The 75% threshold has applied to no live proposal since.

Jul 2026

J&J announces a civil resolution of the ovarian talc litigation: a $5.5 billion commitment, conditioned on participation by at least 95% of remaining claims, with a first payment of no more than $3 billion in 2027.

Sources for the failed plans: Insurance Journal on the July 2023 dismissal of the $8.9 billion plan · Bloomberg Law on the March 2025 Red River Talc ruling and its 75% vote.

What the 2026 Proposal Actually Says

The terms below are quoted from Johnson & Johnson’s own Form 8-K filed with the SEC on July 27, 2026, with case counts and scope confirmed by Reuters’ reporting of July 28, 2026.

Term	As stated in the filing / reporting
Amount	A $5.5 billion commitment by the company. Plaintiffs' lead counsel has said the payout is uncapped and could exceed $7 billion depending on participation.
Condition	Express participation of at least 95% of the remaining claims. Below that, J&J is not bound.
Timing	A first payment of no more than $3 billion in 2027, with no additional payments due before 2028.
Scope	Ovarian talc claims only — the federal MDL in New Jersey plus related state-court cases, described by J&J as nearly all remaining ovarian claims.
Future claims	Not covered. Unlike the bankruptcy plans, this resolves existing claims only; anyone diagnosed later is not bound by it.
Mesothelioma	Not part of this deal. J&J says it has resolved roughly 95% of mesothelioma talc claims separately; new mesothelioma cases continue to be filed and tried.
Status	Proposed, not final. Not court-approved, no claims administrator, no claim form, and no filing deadline exists as of August 14, 2026.

What Individual Payouts Might Look Like

No per-claimant amounts have been published. Counsel have described a tiered grid based on objective claim criteria — factors such as diagnosis, age at diagnosis, and documented product use — but the grid itself is not public, and any site quoting exact tier amounts today is guessing.

What can be stated honestly is the arithmetic:

$5.5 billion spread across roughly 69,000–76,000 claims works out to an average in the region of $72,000–$80,000 per claim before attorney fees, costs, and any medical liens.
If participation drives the total toward the $7 billion that plaintiffs’ counsel has described as possible, that average moves to roughly $92,000 on the same basis.
Contingency fees and case costs typically consume a substantial share of any gross recovery, so the amount actually reaching a claimant is materially lower than the averages above.

An average is not a prediction for any individual case. A tiered grid means some claims land well above these figures and many land well below. Historic jury verdicts — several in the hundreds of millions — are not a guide to settlement values either: they are the rare outliers that survived appeal scrutiny, and many talc cases that reached trial ended in defense verdicts for J&J.

Notable Jury Verdicts

Individual trials produced the verdicts that shaped the litigation and, by most accounts, pushed J&J toward resolution. Verdict amounts are gross awards as returned by the jury; several were later reduced or overturned.

$4.69 billion (2018, St. Louis) — 22 plaintiffs alleging ovarian cancer; reduced to roughly $2.12 billion on appeal.
$1.5 billion (December 2025, Baltimore) — a single plaintiff with peritoneal mesothelioma; reported as the largest single-plaintiff talc verdict to date.
$966 million (October 2025, Los Angeles) — awarded to the family of a woman who died of mesothelioma linked to talc.
$750 million (2023, New Jersey) — mesothelioma after childhood exposure to Baby Powder; later reduced to $185 million.
$72 million (2016, St. Louis) — the first major talc verdict, for the family of a woman who died of ovarian cancer.

Mesothelioma verdicts have continued through 2026 — a Los Angeles jury returned $32 million in June 2026 — which matters because mesothelioma claims sit outside the $5.5 billion ovarian proposal entirely.

Current Status & What Claimants Should Know

As of August 14, 2026, the $5.5 billion resolution is proposed, not concluded. Key considerations:

The 95% condition is real leverage, and real risk. If participation falls short, J&J is not bound and the cases return to the trial track in MDL 2738 and state court.
There is no claim form and no deadline yet. Any website offering to “file your talc settlement claim” today is not processing an approved program. Claim mechanics can only follow a final deal.
Existing claims only. A later diagnosis is not covered by this proposal, and state statutes of limitation continue to run in the meantime.
Mesothelioma is on a separate track and unaffected by the ovarian resolution.
Payment is staged. Even on the announced schedule, the first money moves in 2027, with nothing further due before 2028.

This page is research, not legal advice. Deadlines and eligibility depend on your state and your own case; an attorney licensed in your state is the only reliable source for whether a claim is viable.

Sources

Johnson & Johnson, Current Report on Form 8-K, Item 7.01 — filed with the U.S. Securities and Exchange Commission, July 27, 2026. Primary source for the $5.5 billion commitment, the 95% participation condition, and the 2027/2028 payment schedule.
U.S. Judicial Panel on Multidistrict Litigation, “Pending MDL Dockets by Actions Pending” (PDF) — report dated August 3, 2026. Primary source for the 68,914 pending actions in MDL 2738.
U.S. District Court, District of New Jersey — Johnson & Johnson Talcum Powder Litigation — the court’s own MDL 2738 information page.
Reuters, “Johnson & Johnson Announces $5.5 Billion Settlement of Talc Lawsuits” — July 28, 2026. Scope of the deal, case counts, and statements from both sides.
Insurance Journal / Reuters, “J&J Effort to Resolve Talc Lawsuits in Bankruptcy Fails a Second Time” — July 31, 2023. The dismissal that ended the $8.9 billion plan.
Bloomberg Law, “J&J’s Failed Bid to End Talc Suits Is Bankruptcy Voting Lesson” — on the March 2025 Red River Talc ruling and the 75% vote requirement that applied to it.

Explore More Settlement Research

See how talcum powder settlements compare to other major mass tort litigations and use our calculators to estimate settlement values.

Roundup Settlements NPDB Malpractice Study Estimate Your Settlement

Primary sources

Every figure on this page traces to a dataset published by the agency below. The links go to the agency's own page — not to a summary of it.

Pending MDL dockets by actions pending
U.S. Judicial Panel on Multidistrict Litigation
The authoritative count of cases pending in MDL 2738. Case counts quoted elsewhere should be checked against it.
jpml.uscourts.gov
Johnson & Johnson filings (EDGAR)
U.S. Securities and Exchange Commission
The Form 8-K in which J&J describes the proposal itself, rather than a report about it.
sec.gov
List of Classifications by cancer site
International Agency for Research on Cancer (WHO)
monographs.iarc.who.int

Source files last retrieved August 14, 2026. Agencies revise historical records; figures reflect the files as retrieved on that date.

Cite this analysis

Free to reuse with attribution. The court and agency records behind every figure are linked above — cite them directly when you need the primary document rather than our summary.

APA

Goldberg, L. (2026). Talcum Powder Lawsuit Settlements — the Johnson & Johnson talc litigation and its proposed resolutions [Analysis of public records]. Settlement Insight Research. https://settlementinsight.com/research/talcum-powder-settlements

BibTeX

@misc{goldberg_2026_talcum,
  author       = {Goldberg, Leonard},
  title        = {{Talcum Powder Lawsuit Settlements -- the Johnson \& Johnson
                  talc litigation and its proposed resolutions}},
  year         = 2026,
  howpublished = {Settlement Insight Research},
  url          = {https://settlementinsight.com/research/talcum-powder-settlements}
}

Mass Tort Research

Talcum Powder Settlements: J&J’s $5.5 Billion 2026 Proposal

Figures on this page are sourced to J&J’s Form 8-K filed with the SEC on July 27, 2026 and the JPML pending-case report dated August 3, 2026. Last reviewed August 14, 2026.

Updated August 14, 2026 — earlier figures superseded

$5.5B

J&J Commitment (Proposed)

Announced July 27, 2026 — SEC Form 8-K

95%

Required Participation

Deal is void below this threshold

68,914

Pending MDL 2738 Cases

JPML report, August 3, 2026

2027

Earliest Payments

Up to $3B in 2027; nothing more before 2028

Background: Why Talcum Powder Lawsuits Exist

J&J discontinued talc-based Baby Powder in the United States and Canada in 2020 and globally in 2023, switching to a cornstarch-based formula.

Key Timeline

Three attempts to end this litigation through bankruptcy failed before J&J returned to civil court. That sequence explains why older “settlement amounts” still circulate online.

2018

A Reuters investigation reports that J&J knew about asbestos findings in its talc for decades. Filings surge nationwide.

2018

A St. Louis jury awards $4.69 billion to 22 women alleging talc caused ovarian cancer — later reduced to roughly $2.12 billion on appeal.

2020

J&J discontinues talc-based Baby Powder in the U.S. and Canada; the global discontinuation follows in 2023.

2021

J&J moves talc liabilities into a subsidiary, LTL Management, and puts it into Chapter 11 — the "Texas Two-Step." The Third Circuit orders the case dismissed in 2023.

Apr 2023

In a second Chapter 11, J&J proposes an $8.9 billion fund payable over 25 years. This is the origin of the "$8.9 billion settlement" figure still quoted across the web.

Jul 2023

2024

J&J proposes a roughly $6.5 billion ovarian-only plan and, in September, places a new subsidiary, Red River Talc, into a prepackaged Chapter 11 requiring a 75% claimant vote.

Mar 2025

Jul 2026

Sources for the failed plans: Insurance Journal on the July 2023 dismissal of the $8.9 billion plan · Bloomberg Law on the March 2025 Red River Talc ruling and its 75% vote.

What the 2026 Proposal Actually Says

The terms below are quoted from Johnson & Johnson’s own Form 8-K filed with the SEC on July 27, 2026, with case counts and scope confirmed by Reuters’ reporting of July 28, 2026.

Term	As stated in the filing / reporting
Amount	A $5.5 billion commitment by the company. Plaintiffs' lead counsel has said the payout is uncapped and could exceed $7 billion depending on participation.
Condition	Express participation of at least 95% of the remaining claims. Below that, J&J is not bound.
Timing	A first payment of no more than $3 billion in 2027, with no additional payments due before 2028.
Scope	Ovarian talc claims only — the federal MDL in New Jersey plus related state-court cases, described by J&J as nearly all remaining ovarian claims.
Future claims	Not covered. Unlike the bankruptcy plans, this resolves existing claims only; anyone diagnosed later is not bound by it.
Mesothelioma	Not part of this deal. J&J says it has resolved roughly 95% of mesothelioma talc claims separately; new mesothelioma cases continue to be filed and tried.
Status	Proposed, not final. Not court-approved, no claims administrator, no claim form, and no filing deadline exists as of August 14, 2026.

What Individual Payouts Might Look Like

What can be stated honestly is the arithmetic:

$5.5 billion spread across roughly 69,000–76,000 claims works out to an average in the region of $72,000–$80,000 per claim before attorney fees, costs, and any medical liens.
If participation drives the total toward the $7 billion that plaintiffs’ counsel has described as possible, that average moves to roughly $92,000 on the same basis.
Contingency fees and case costs typically consume a substantial share of any gross recovery, so the amount actually reaching a claimant is materially lower than the averages above.

Notable Jury Verdicts

$4.69 billion (2018, St. Louis) — 22 plaintiffs alleging ovarian cancer; reduced to roughly $2.12 billion on appeal.
$1.5 billion (December 2025, Baltimore) — a single plaintiff with peritoneal mesothelioma; reported as the largest single-plaintiff talc verdict to date.
$966 million (October 2025, Los Angeles) — awarded to the family of a woman who died of mesothelioma linked to talc.
$750 million (2023, New Jersey) — mesothelioma after childhood exposure to Baby Powder; later reduced to $185 million.
$72 million (2016, St. Louis) — the first major talc verdict, for the family of a woman who died of ovarian cancer.

Current Status & What Claimants Should Know

As of August 14, 2026, the $5.5 billion resolution is proposed, not concluded. Key considerations:

The 95% condition is real leverage, and real risk. If participation falls short, J&J is not bound and the cases return to the trial track in MDL 2738 and state court.
There is no claim form and no deadline yet. Any website offering to “file your talc settlement claim” today is not processing an approved program. Claim mechanics can only follow a final deal.
Existing claims only. A later diagnosis is not covered by this proposal, and state statutes of limitation continue to run in the meantime.
Mesothelioma is on a separate track and unaffected by the ovarian resolution.
Payment is staged. Even on the announced schedule, the first money moves in 2027, with nothing further due before 2028.

Sources

Johnson & Johnson, Current Report on Form 8-K, Item 7.01 — filed with the U.S. Securities and Exchange Commission, July 27, 2026. Primary source for the $5.5 billion commitment, the 95% participation condition, and the 2027/2028 payment schedule.
U.S. Judicial Panel on Multidistrict Litigation, “Pending MDL Dockets by Actions Pending” (PDF) — report dated August 3, 2026. Primary source for the 68,914 pending actions in MDL 2738.
U.S. District Court, District of New Jersey — Johnson & Johnson Talcum Powder Litigation — the court’s own MDL 2738 information page.
Reuters, “Johnson & Johnson Announces $5.5 Billion Settlement of Talc Lawsuits” — July 28, 2026. Scope of the deal, case counts, and statements from both sides.
Insurance Journal / Reuters, “J&J Effort to Resolve Talc Lawsuits in Bankruptcy Fails a Second Time” — July 31, 2023. The dismissal that ended the $8.9 billion plan.
Bloomberg Law, “J&J’s Failed Bid to End Talc Suits Is Bankruptcy Voting Lesson” — on the March 2025 Red River Talc ruling and the 75% vote requirement that applied to it.

Explore More Settlement Research

See how talcum powder settlements compare to other major mass tort litigations and use our calculators to estimate settlement values.

Roundup Settlements NPDB Malpractice Study Estimate Your Settlement

Primary sources

Every figure on this page traces to a dataset published by the agency below. The links go to the agency's own page — not to a summary of it.

Pending MDL dockets by actions pending
U.S. Judicial Panel on Multidistrict Litigation
The authoritative count of cases pending in MDL 2738. Case counts quoted elsewhere should be checked against it.
jpml.uscourts.gov
Johnson & Johnson filings (EDGAR)
U.S. Securities and Exchange Commission
The Form 8-K in which J&J describes the proposal itself, rather than a report about it.
sec.gov
List of Classifications by cancer site
International Agency for Research on Cancer (WHO)
monographs.iarc.who.int

Source files last retrieved August 14, 2026. Agencies revise historical records; figures reflect the files as retrieved on that date.

Cite this analysis

Free to reuse with attribution. The court and agency records behind every figure are linked above — cite them directly when you need the primary document rather than our summary.

APA

BibTeX

@misc{goldberg_2026_talcum,
  author       = {Goldberg, Leonard},
  title        = {{Talcum Powder Lawsuit Settlements -- the Johnson \& Johnson
                  talc litigation and its proposed resolutions}},
  year         = 2026,
  howpublished = {Settlement Insight Research},
  url          = {https://settlementinsight.com/research/talcum-powder-settlements}
}